A-005 SAD/MAD Study in Healthy Adults

Phase 1, randomised, double-blind trial of A-005, sponsored by Alumis Inc. Primary endpoints: Incidence of nonserious adverse events, serious adverse events, and adverse events in single oral dose administration at 4 days and Incidence of nonserious adverse events, serious adverse events, and adverse events in multiple oral dose administration at 17 days. Started Apr 2024; status: completed.